Uncategorized

FDA uncertainty adds risk to biopharma deals

Published

on

While merger and acquisition activity has been robust of late, frequent changes in guidance and leadership at the regulator add risk to any transaction.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version